American Heart Association and European Society of Cardiology new guidelines have added a class of diabetes drugs called SGLT-2 inhibitors (empagliflozin, dapagliflozin) to the list of treatments for heart failure [14,15]. The gene discussed is SLC5A2; the disease is diabetes mellitus.